Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 201 participants.
Also called NCT04079192
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 201 participants
- Sponsor
- Registry
-
NCT04079192
-
- Other papers using this trial's data
- Final 2-Year Results of the REFORM Study: A Randomized Trial of Biolimus DCB Versus Paclitaxel DCB for In-Stent Restenosis
- Randomized Trial of Biolimus DCB for In-Stent Restenosis: The Primary Results of the REFORM Study
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Germany, Ireland, Italy, Spain, United Kingdom
- Registry status
- Unknown status
Technical summary
Registry record NCT04079192. Randomized; single masking; primary purpose treatment. Start 2020-08-07 (actual); primary completion 2023-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) Study
- Acronym
- REFORM
- Condition
- Coronary Artery Disease
- Condition
- In-Stent Restenosis
- Intervention (Device)
- Biolimus A9 Drug Coated Balloon
- Intervention (Device)
- SeQuent Please Paclitaxel Drug Coated Balloon
- Lead sponsor
- Biosensors Europe SA
Record details
- Record id
cardio:ct-nct04079192- Content hash
58799a37facb2a4cbcb86ea315266597e90acc703396e9c568021cbd9b8507e1